The price of interoperable layer-1 protocol Injective (INJ) has shown its bullish side in recent trading days, leading the list of top performers among the 100 largest altcoins with a 12 percent price gain.

In the last 24 hours of trading, the price of INJ has continued to increase in value, rising nearly 3 percentage points to the north.

Injective's price is currently benefiting from the integration of the Paypal stablecoin PYUSD, which is intended to facilitate the onboarding of users on the Layer1 blockchain, which specializes in decentralized finance.

In the wake of recent weakness in the crypto market, the INJ price initially bounced off the key resistance area between $31.49 and $32.78 in recent days, initially heading south. However, as long as the bulls manage to stabilize the price above the weekly low of $26.39, a new attack toward the weekly high of just under $33 can be expected at any time.

If the bulls then manage to lift the price above this for a sustained period, the next price target around $35.79 immediately comes into view.

If the INJ share price is also able to dynamically break through this price target level, an advance to the interim high of $40.86 on March 26 can be planned. This is also the golden pocket of the recent recovery.

If the buying party subsequently succeeds in stabilizing Injective's share price above this level, the likelihood of a further price bump up to the zone around the 2023 high of $45.40 increases. The stock price is likely to fail here on the first attempt.

If the altcoin stabilizes above this resistance zone in the medium term, an advance to this year's March all-time high at $53.09 can be expected. Profit-taking should also be expected here.

If the price jumps to new medium-term highs in the wake of renewed strength in the crypto market, the maximum short price target should be upside at $62.60. This is where the 127 Fib price target lies. This is the 127 Fibonacci extension of the current price movement.

On the other hand, if the INJ price slides southward again and breaks through the $26.05 support zone, a retest of the zone around last month's low between $21.98 and $21.33 can be expected.

If the bulls remain abstinent here and this zone is finally exited, the corrective move could extend to the striking low of $18.14 reached on April 13.

If, contrary to prediction, Injective's share price also breaks through this key support zone in the course of a sustained general market correction, a sell-off back to the November 2023 lows of $14.22 can no longer be ruled out.